Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: Results of the Duesseldorf study

Hematological Oncology

Volumn 26, Issue 4, 2008, Pages 213-218

  Neumann, Frank ^a   Markett, Judith ^a   Fenk, Roland ^a   Pooten, Monika ^a   Koch, Anne ^a   Bruennert, Daniela ^a   Schimkus, Nadine ^a   Wulfert, Michael ^a   Royer Pokora, Brigitte ^a   Kronenwett, Ralf ^a,b   Haas, Rainer ^a   Gatterman, Norbert ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Siemens Medical Solutions Diagnostics   (Germany)

Author keywords

Chronic myelogenous leukaemia; Dose escalation; Imatinib; Molecular monitoring

Indexed keywords

BCR ABL PROTEIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IMATINIB; MESSENGER RNA; NILOTINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA REMISSION; MALE; MOLECULAR THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD CELL COUNT; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MUTATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PYRIMIDINES; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 58949098944     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.860     Document Type: Article

References (45)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
2. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, et al. on behalf of the Chronic Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461-467.
3. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
5. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable haematological and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 6: 1928-1937.
6. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. International STI571 CML Study Group. The International Imatinib CML Study Group. Haematological and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 9: 645-652.
7. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate (IMATINIB) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 10: 3547-3553.
8. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces haematological and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crisis. Results of a phase II study. Blood 2002; 99: 3530-3539.
9. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. JT N Engl J Med 2003; 348: 994-1004.
10. Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003; 17: 2401-2409.
11. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007; 109: 1556-1560.
12. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101: 473-475.
13. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 2007; Feb 22, 109: 5143-5150 [Epub ahead of print].
14. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL. N Engl J Med 2006; 354: 2542-2551.
15. Neumann F, Herold C, Hildebrandt B, Kobbe G, Aivado M, Rong A, et al. Quantitative real-time RT-PCR for diagnosis of bcr-abl positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol 2003; 70: 1-10.
16. Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 9: 1579-1583.
17. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reactionmethod in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol 2000; 79: 424-431.
18. Kreuzer KA, Lass U, Bohn A, Landt O, Schmidt CA. Light-Cycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 1999; 59: 3171-3174.
19. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.
20. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62-66.
21. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001; 97: 1560-1565.
22. Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL, Hokland P. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with Imatinib measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2001; 67: 302-308.
23. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to Imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118: 771-777.
24. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or Interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
25. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
26. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-3475.
27. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-2878.
28. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820. 28.
29. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukaemia 2006; 20: 1925-1930.
30. Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, et al. Emergence of clonal cytogenetic abnormalities in ph-negative cells in some CML patients in cytogenetic remission to Imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941-1949.
31. Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, et al. France Intergroupe pour la Leucemie Myeloide Chronique. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340-1346.
32. Bacher U, Hochhaus A, Berger U, Hiddemann W, Hehlmann R, Haferlach T, et al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2005; 19: 460-463.
33. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390-1395.
34. Fabarius A, Giehl M, Frank O, Duesberg P, Hochhaus A, Hehlmann R, et al. Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 2005; 19: 1573-1578.
35. Neumann F, Teutsch N, Kliszewski S, Bork S, Steidl U, Brors B, et al. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. Leukemia 2005; 19: 458-460.
36. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926-2932.
37. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
38. Yamamoto M, Kakihana K, Kurosu T, Murakami N, Miura O. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet 2005; 157: 104-108.
39. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-698.
40. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739-3745.
41. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003; 9: 2092-2097.
42. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
43. O'Hare T,Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-4505.
44. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.
45. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2309.